Managing Director at RMG, Lisa is a drug development executive and thought leader whose scientific, regulatory, operational and business experience uniquely positions her to assess, develop and optimize pharmaceutical strategy. Lisa has over 20 years of global experience driving the development and execution of pharmaceutical strategy, developing and leading teams and transformations that have delivered significant results in multiple therapeutic areas including oncology, anti-infectives, and vaccines. Lisa’s experience includes large and small molecules and devices in all research and development phases.

Prior to joining RM Global, Lisa founded S3B Consulting in 2014 to help biotech startups translate their science into drug development strategy. Since S3B’s inception, she has guided multiple startups as they selected their lead indication and developed their business plan in support of their fund raising activities. From 2012 to 2014, Lisa was the VP of R&D Operations for Ikaria. During her tenure, she successfully reorganized and upgraded Project Management, Clinical Operations and Contracts & Outsourcing departments, and implemented Ikaria’s first portfolio assessment, resulting in the identification and alignment of key risks to be addressed by programs.

From 2008 to 2012 Lisa was Executive Director, Global Program Leader for Celgene. Under her leadership, the business case and global registration program for pomalidomide (projected sales of over $1B in the next five years) were developed and endorsed by executive management. Lisa led the plan up to successful NDA submission leading to approval in both the US and EU. Prior to 2008, while at Novartis and Chiron, Lisa successfully led organizations through the challenging process of identifying the optimal strategy and operational plan to balance business and science, ensuring on time delivery, a successful approval, and maximized ROI.

Lisa received her BS from University of Illinois and her MS and PhD from North Carolina State University, where she graduated Xi Sigma Pi and Sigma Xi, respectively. Following her PhD, she completed a post-doc at Washington University in St Louis. She serves as an Executive in Residence at Mount Sinai Innovation Partners.